First Opinion By Joe Gray, Lindsay Morton and Gayle Woloschak The U.S. needs to revitalize research on the health effects of low-dose radiation
Health By Matthew Herper FDA authorizes Pfizer and Moderna Covid vaccines for infants, toddlers, and preschoolers
First Opinion By Christi A. Grimm, Ruth Ann Dorrill and Julie K. Taitsman New report: gains in patient safety have stalled over the past decade
Pharmalot By Ed Silverman FDA oversight of pharma manufacturing facilities plunges during the pandemic
Hospitals By Tara Bannow The FTC says it’s getting tougher on hospital consolidation. Antitrust experts aren’t buying it
Pharmalot By Ed Silverman Quantity over quality: FDA approved more cancer drugs than EMA, but they may not have always benefited patients
The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein Listen: Juul’s doomsday, Merck’s buyout plans, & the next Theranos verdict
Politics By Nicholas Florko Despite fanfare, the FDA’s step toward lowering nicotine levels in cigarettes is a very early one
Pharmalot By Ed Silverman Senate lawmakers introduce a bill to help the FDA and the U.S. Patent Office coordinate
Pharmalot By Ed Silverman Pharmalittle: Lawmakers urge FTC to probe blood thinner prices; EU pressures Covid vaccine makers to renegotiate contracts
First Opinion By Steve Brozak and Richard Marfuggi Lessons from earlier pandemics: Vaccine panel must discuss imprinting among infants and toddlers
Pharmalot By Ed Silverman Pharmalittle: Canada OKs ALS drug still waiting FDA approval; WTO talks on Covid patent waiver are down to the wire
Pharmalot By Ed Silverman Pharmalittle: FDA panel endorses Bluebird Bio gene therapy for rare disease; GSK touts RSV vaccine trial results
Health By Helen Branswell and Andrew Joseph ‘Testing bottleneck’ for monkeypox puts hope of containment at risk, experts warn
Politics By Lev Facher Francis Collins: Concern about independence of new moonshot science agency ARPA-H are ‘overblown’
First Opinion By Peter J. Pitts Beyond baby formula: advancing best practices in FDA’s efforts to prevent shortages
Pharmalot By Ed Silverman Documents show problems at Novartis facility where cancer drug production was halted
Politics By Rachel Cohrs Biden administration won’t lower seniors’ Medicare premiums this year, despite changes to coverage of new Alzheimer’s drug
Politics By Lev Facher Key Senate committee proposes a council to ensure FDA better coordinates on accelerated approvals
Politics By Nicholas Florko The FDA says it’s in the dark about thousands of dietary supplement ingredients
Health By Matthew Herper CDC recommends Covid boosters for kids ages 5 to 11 after advisory committee vote
Exclusive By Nicholas Florko Senate FDA legislation will include dietary supplement, cosmetic reforms
Pharmalot By Ed Silverman National Institutes of Health licenses nearly a dozen Covid-19 technologies to a WHO program
Health Tech By Mario Aguilar The FDA eased rules for mental health apps during the pandemic. Now companies are bracing for it to tighten the reins
Politics By Lev Facher The panel was supposed to improve efficiency at the NIH. It hasn’t even met for 7 years
First Opinion By Brian Barnett Flawed FDA safety requirements are hamstringing a highly effective treatment for severe schizophrenia
Pharmalot By Ed Silverman FDA warns Miami University contract testing lab over falsified data, poor quality control